SCHEDULE: Galera Therapeutics: Director Chang's Stake and Merger Update

Nancy T. Chang, a director of Galera Therapeutics, Inc., has updated her beneficial ownership following a merger and private placement, now holding 5.9% of the company's common stock.

Summary

• Nancy T. Chang, a director of Galera Therapeutics, Inc., has filed a Schedule 13D detailing her beneficial ownership of the company's common stock.
• As of April 10, 2026, Ms. Chang beneficially owns 8,921,543 shares of common stock, representing approximately 5.9% of the outstanding shares.
• This ownership includes 8,825,543 shares of common stock and a stock option to purchase an additional 96,000 shares.
• The filing details her participation in a December 30, 2024, private placement where she purchased 7,644,932 shares for approximately $499,979.
• It also covers the merger of Galera Therapeutics with Nova Pharmaceuticals, Inc., effective December 30, 2024, in which Ms. Chang received Series B Convertible Preferred Stock.
• Subsequent to the merger, a partial mandatory conversion on April 7, 2026, converted 1,180.611 shares of Series B Preferred Stock into 1,180,611 shares of common stock, leaving her with 661.309 shares of Series B Preferred Stock.
• Ms. Chang acquired these securities for investment purposes and in her capacity as a director.
• The filing also references support agreements, lock-up agreements, and a registration rights agreement related to the merger and private placement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting significant corporate restructuring and financing activities. While the merger and private placement indicate strategic moves, the decrease in ownership percentage and the complexities surrounding preferred stock conversion introduce some caution.

Positives

• Nancy T. Chang, a director, has increased her direct shareholding through a private placement, indicating continued investment in the company.
• The merger with Nova Pharmaceuticals, Inc. has been completed, potentially creating a more robust entity.
• Ms. Chang holds an option to purchase additional shares, providing potential for future equity growth.
• A registration rights agreement is in place to facilitate the resale of shares held by investors, including Ms. Chang, which can improve liquidity.

Negatives

• Ms. Chang's beneficial ownership percentage has decreased from approximately 10.1% as of December 30, 2024, to 5.9% as of April 10, 2026, due to share issuances and conversions.
• The conversion of Series B Preferred Stock into common stock is subject to future shareholder approval, creating uncertainty.
• A significant portion of Ms. Chang's Series B Preferred Stock remains unconverted and requires shareholder approval for conversion.

Risks

• The conversion of Series B Preferred Stock into common stock requires future shareholder approval, which may not be obtained.
• The company may need to increase the number of authorized shares or effect a reverse stock split, subject to shareholder approval.
• Ms. Chang, as a director, may influence corporate activities, which could lead to strategic shifts or governance changes.
• Future stock purchases or sales by Ms. Chang could impact the stock price.
• The registration statement for resale of securities may face delays in SEC effectiveness.

Future Outlook

The company plans to submit matters to stockholders for consideration, including the approval of the conversion of Series B Preferred Stock into Common Stock, and potential amendments to the certificate of incorporation for a reverse stock split and/or increase in authorized shares. The Registration Rights Agreement mandates the filing of a registration statement for resale of securities within 90 days of the private placement closing, with an effectiveness deadline of 30-60 days thereafter. Ms. Chang intends to review her investment on a continuing basis and may engage in various transactions, including purchasing or selling shares, and communicating with stakeholders regarding company matters.

Management Comments

• The Reporting Person acquired the securities reported herein for investment purposes and in her capacity as a director on the Board effective as of December 30, 2024.
• The Reporting Person expects to review her investment on a continuing basis.
• As a member of the Board, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D.
• Subject to applicable legal requirements, and depending on market and other conditions, the Reporting Person may (i) purchase additional shares of Common Stock, options, or related derivatives in the open market, in privately negotiated transactions, or otherwise; (ii) sell all or a portion of the shares of Common Stock, options, or related derivatives now beneficially owned or hereafter acquired; (iii) engage in communications with, without limitation, one or more shareholders of the Issuer, one or more officers of the Issuer and/or one or more members of the Board regarding the Issuer, including but not limited to its operations, governance, and control; and (iv) engage in other proposals as the Reporting Person may deem appropriate under the circumstances, including plans or proposals which may relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D.

Industry Context

StockSavvy.ai notes that this filing reflects significant corporate activity for Galera Therapeutics, including a merger and a private placement. Such actions are common in the biotechnology sector as companies seek to strengthen their financial position, expand their pipeline, or achieve strategic growth objectives. The involvement of a director in these transactions, as detailed in this Schedule 13D, highlights ongoing strategic engagement and potential influence on the company's direction.

Comparison to Industry Standards

• The private placement price of $0.0654 per share is significantly below typical biotech IPO or follow-on offering prices, suggesting a distressed valuation or a specific strategic financing round.
• The merger with Nova Pharmaceuticals, Inc. is a common strategy in the biotech industry to consolidate resources, gain access to new technologies, or achieve economies of scale. Competitors like Amgen and Pfizer frequently engage in similar M&A activities, though typically at much larger scales and valuations.
• The structure involving Series B Convertible Preferred Stock and subsequent mandatory conversions is a financing mechanism sometimes used to defer dilution or provide flexibility, though it introduces complexity and potential future dilution risks not always present in standard equity offerings.
• The 90-day lock-up period for certain securityholders is a standard practice following mergers and private placements to prevent immediate selling pressure and stabilize the stock price, aligning with industry norms.

Corporate Governance

Related Party Transactions

• Nancy T. Chang, a director, participated in the December 30, 2024, private placement, purchasing 7,644,932 shares of Common Stock for approximately $499,979.
• Nancy T. Chang received 1,841.92 shares of Series B Non-Voting Convertible Preferred Stock in exchange for shares of Nova Pharmaceuticals, Inc. common stock as part of the merger transaction.
• Nancy T. Chang entered into a stockholder support agreement and a lock-up agreement in connection with the merger and private placement.

Stakeholder Impact

• Shareholders: Potential dilution from the conversion of Series B Preferred Stock and the exercise of stock options. Changes in authorized share count or reverse stock splits could also impact share structure. Registration rights may improve liquidity for certain investors.
• Employees: The merger and potential corporate restructuring could impact employee roles and operations. The stock option grant to Ms. Chang is a form of compensation.
• Creditors: Changes in the company's financial structure and capital raise activities could affect its debt profile and ability to service obligations.

Next Steps

• Galera Therapeutics will submit matters to its stockholders for consideration, including approval of the conversion of Series B Preferred Stock into Common Stock.
• Approval of an amendment to the Issuer's certificate of incorporation for a reverse stock split and/or increase in authorized shares may be sought.
• The Issuer is obligated to prepare and file a registration statement for the resale of Registrable Securities within 90 days of the December 2024 Private Placement closing.
• The registration statement is expected to be declared effective by the SEC within 30-60 days of filing.
• Nancy T. Chang will continue to review her investment and may engage in further transactions or communications regarding the Issuer.

Key Dates

Recommendation

The filing details significant corporate actions including a merger and a private placement, along with changes in a director's beneficial ownership. While these indicate strategic activity, the decrease in ownership percentage, the complexity of preferred stock conversions requiring future shareholder approval (though some waivers have occurred), and the overall financial health implied by the private placement price warrant a cautious 'hold' stance pending further clarity on the integration and future performance post-merger.

Keywords

Galera Therapeutics, Schedule 13D, Nancy T. Chang, Merger, Nova Pharmaceuticals, Private Placement, Beneficial Ownership, Common Stock, Series B Preferred Stock, Stock Option, Registration Rights, Director